Stress-related depression: Neuroendocrine, genetic, and therapeutical aspects

World Journal of Biological Psychiatry

Volumn 13, Issue 8, 2012, Pages 556-568

  Bosch, Oliver G ^a   Seifritz, Erich ^a   Wetter, Thomas C ^a  

^a UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

Author keywords

antidepressant response; depression; genetics; neuroendocrinology; Stress

Indexed keywords

3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; ALPRAZOLAM; ANTALARMIN; BENZODIAZEPINE DERIVATIVE; BRAIN DERIVED NEUROTROPHIC FACTOR; CITALOPRAM; CORTICOSTEROID RECEPTOR; CORTICOTROPIN RELEASING FACTOR; DULOXETINE; ESCITALOPRAM; FK 506 BINDING PROTEIN; MIFEPRISTONE; MIRTAZAPINE; MOCLOBEMIDE; OXYTOCIN; PAROXETINE; SEROTONIN; STRESS HORMONE; VENLAFAXINE;

ANTIDEPRESSANT ACTIVITY; DEPRESSION; DRUG RESPONSE; DRUG SUBSTITUTION; ENVIRONMENTAL FACTOR; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENETICS; HEREDITY; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MAJOR DEPRESSION; META ANALYSIS (TOPIC); NEGATIVE FEEDBACK; NEUROENDOCRINOLOGY; NONHUMAN; RECEPTOR GENE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STRESS; SYSTEMATIC REVIEW (TOPIC); TRANQUILIZING ACTIVITY; TREATMENT RESPONSE;

DEPRESSION; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; PITUITARY-ADRENAL SYSTEM; STRESS, PSYCHOLOGICAL;

EID: 84869150223     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622975.2012.665477     Document Type: Review

References (151)

1. Anacker C, Zunszain PA, Cattaneo A, Carvalho LA, Garabedian MJ, Thuret S, et al. 2011. Antidepressants increase human hippocampal neurogenesis by activating the glucocorticoid receptor. Mol Psychiatry 16:738-50.
2. Anguelova M, Benkelfat C, Turecki G. 2003. A systematic review of association studies investigating genes coding for serotonin receptors and the serotonin transporter: I. Affective disorders. Mol Psychiatry 8:574-591. (Pubitemid 36898017)
3. Appel K, Schwahn C, Mahler J, Schulz A, Spitzer C, Fenske K, et al. 2011. Moderation of adult depression by a polymorphism in the FKBP5 gene and childhood physical abuse in the general population. Neuropsychopharmacology 36: 1982-1991.
4. Bachmann CG, Linthorst AC, Holsboer F, Reul JM. 2003. Effect of chronic administration of selective glucocorticoid receptor antagonists on the rat hypothalamic-pituitary-adrenocortical axis. Neuropsychopharmacology 28:1056-1067.
5. Baghai TC, Binder EB, Schule C, Salyakina D, Eser D, Lucae S, et al. 2006. Polymorphisms in the angiotensin-converting enzyme gene are associated with unipolar depression, ACE activity and hypercortisolism. Mol Psychiatry 11: 1003-1015. (Pubitemid 44631643)
6. Barbaccia ML. 2004. Neurosteroidogenesis: relevance to neurosteroid actions in brain and modulation by psychotropic drugs. Crit Rev Neurobiol 16(1-2):67-74. (Pubitemid 39586904)
7. Behan DP, Potter E, Lewis KA, Jenkins NA, Copeland N, Lowry PJ, Vale WW. 1993. Cloning and structure of the human corticotrophin releasing factor-binding protein gene (CRHBP). Genomics 16:63-68. (Pubitemid 23123792)
8. Binder EB. 2009. The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders. Psychoneuroendocrinology 34(Suppl 1):S186-195.
9. Binder EB, Holsboer F. 2006. Pharmacogenomics and antidepressant drugs. Ann Med 38:82-94.
10. Binder EB, Nemeroff CB. 2010. The CRF system, stress, depression and anxiety-insights from human genetic studies. Mol Psychiatry 15:574-588.
11. Binder EB, Salyakina D, Lichtner P, Wochnik GM, Ising M, Putz B, et al. 2004. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet 36: 1319-1325. (Pubitemid 39577942)
12. Binder EB, Kunzel HE, Nickel T, Kern N, Pfennig A, Majer M, et al. 2009. HPA-axis regulation at in-patient admission is associated with antidepressant therapy outcome in male but not in female depressed patients. Psychoneuroendocrinology 34:99-109.
13. Binder EB, Owens MJ, Liu W, Deveau TC, Rush AJ, Trivedi MH, et al. 2010. Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response. Arch Gen Psychiatry 67:369-379.
14. Binneman B, Feltner D, Kolluri S, Shi Y, Qiu R, Stiger T. 2008. A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. Am J Psychiatry 165:617-620. (Pubitemid 351705339)
15. Boorse GC, Denver RJ. 2006. Widespread tissue distribution and diverse functions of corticotropin-releasing factor and related peptides. Gen Comp Endocrinol 146:9-18. (Pubitemid 43248702)
16. Bosch OG, Quednow BB, Seifritz E, Wetter TC. 2011. Reconsidering GHB: orphan drug or new model antidepressant? J Psychopharmacol 108:6621-5.
17. Bosker FJ, Hartman CA, Nolte IM, Prins BP, Terpstra P, Posthuma D, et al. 2011. Poor replication of candidate genes for major depressive disorder using genome-wide association data. Mol Psychiatry 16:516-532.
18. Bradley RG, Binder EB, Epstein MP, Tang Y, Nair HP, Liu W, et al. 2008. Infl uence of child abuse on adult depression: moderation by the corticotropin-releasing hormone receptor gene. Arch Gen Psychiatry 65:190-200. (Pubitemid 351214318)
19. Caspi A, Sugden K, Moffi tt TE, Taylor A, Craig IW, Harrington H, et al. 2003. Infl uence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301: 386-389. (Pubitemid 36877077)
20. Chowdrey HS, Larsen PJ, Harbuz MS, Jessop DS, Aguilera G, Eckland DJ, Lightman SL. 1995. Evidence for arginine vasopressin as the primary activator of the HPA axis during adjuvant-induced arthritis. Br J Pharmacol 116:2417-2424.
21. Claes S. 2009. Glucocorticoid receptor polymorphisms in major depression. Ann NY Acad Sci 1179:216-228.
22. Clarke H, Flint J, Attwood AS, Munafo MR. 2010. Association of the 5-HTTLPR genotype and unipolar depression: a metaanalysis. Psychol Med 40:1767-1778.
23. Cyranowski JM, Hofkens TL, Frank E, Seltman H, Cai HM, Amico JA. 2008. Evidence of dysregulated peripheral oxytocin release among depressed women. Psychosom Med 70: 967-975.
24. de Kloet ER, Derijk RH, Meijer OC. 2007. Therapy Insight: is there an imbalanced response of mineralocorticoid and glucocorticoid receptors in depression? Nat Clin Pract Endocrinol Metab 3:168-179. (Pubitemid 46146969)
25. de Quervain DJ, Bentz D, Michael T, Bolt OC, Wiederhold BK, Margraf J, Wilhelm FH. 2011. Glucocorticoids enhance extinction-based psychotherapy. Proc Natl Acad Sci USA 108: 6621-5.
26. DeRijk RH, de Kloet ER. 2008. Corticosteroid receptor polymorphisms: determinants of vulnerability and resilience. Eur J Pharmacol 583(2-3):303-311.
27. DeRijk RH, de Kloet ER, Zitman FG, van Leeuwen N. 2011. Mineralocorticoid receptor gene variants as determinants of HPA axis regulation and behavior. Endocr Dev 20:137-148.
28. Deyoung CG, Cicchetti D, Rogosch FA. 2011. Moderation of the association between childhood maltreatment and neuroticism by the corticotropin-releasing hormone receptor 1 gene. J Child Psychol Psychiatry 52:898-906.
29. Drago A, De Ronchi D, Serretti A. 2009. Pharmacogenetics of antidepressant response: an update. Hum Genomics 3: 257-274.
30. Dudley KJ, Li X, Kobor MS, Kippin TE, Bredy TW. 2011. Epigenetic mechanisms mediating vulnerability and resilience to psychiatric disorders. Neurosci Biobehav Rev [Epub ahead of print].
31. Elder BL, Mosack V. 2011. Genetics of depression: an overview of the current science. Issues Ment Health Nurs 32: 192-202.
32. Feder A, Nestler EJ, Charney DS. 2009. Psychobiology and molecular genetics of resilience. Nat Rev Neurosci 10: 446-457.
33. Fekete EM, Zorrilla EP. 2007. Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: ancient CRF paralogs. Front Neuroendocrinol 28:1-27. (Pubitemid 46533855)
34. Fish EW, Shahrokh D, Bagot R, Caldji C, Bredy T, Szyf M, Meaney MJ. 2004. Epigenetic programming of stress responses through variations in maternal care. Ann NY Acad Sci 1036: 167-180. (Pubitemid 40576094)
35. Gallagher JP, Orozco-Cabal LF, Liu J, Shinnick-Gallagher P. 2008. Synaptic physiology of central CRH system. Eur J Pharmacol 583(2-3):215-225.
36. Gex-Fabry M, Eap CB, Oneda B, Gervasoni N, Aubry JM, Bondolfi G, Bertschy G. 2008. CYP2D6 and ABCB1 genetic variability: infl uence on paroxetine plasma level and therapeutic response. Ther Drug Monit 30:474-482.
37. Glessner JT, Wang K, Sleiman PM, Zhang H, Kim CE, Flory JH, et al. 2010. Duplication of the SLIT3 locus on 5q35.1 predisposes to major depressive disorder. PLoS One 5:e15463.
38. Grabe HJ, Schwahn C, Appel K, Mahler J, Schulz A, Spitzer C, et al. 2010. Childhood maltreatment, the corticotropin-releasing hormone receptor gene and adult depression in the general population. Am J Med Genet B Neuropsychiatr Genet 153B(8):1483-1493.
39. Griebel G, Perrault G, Sanger DJ. 1998. Characterization of the behavioral profi le of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents. Comparison with diazepam and buspirone. Psychopharmacology (Berlin) 138:55-66. (Pubitemid 28319048)
40. Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, Scatton B, et al. 2002. Anxiolytic-and antidepressantlike effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc Natl Acad Sci USA 99:6370-6375. (Pubitemid 34493318)
41. Grigoriadis DE. 2005. The corticotropin-releasing factor receptor: a novel target for the treatment of depression and anxietyrelated disorders. Expert Opin Ther Targets 9:651-684. (Pubitemid 41131672)
42. Groves JO. 2007. Is it time to reassess the BDNF hypothesis of depression? Mol Psychiatry 12:1079-1088. (Pubitemid 350191365)
43. Gysling K, Forray MI, Haeger P, Daza C, Rojas R. 2004. Corticotropin-releasing hormone and urocortin: redundant or distinctive functions? Brain Res Brain Res Rev 47: 116-125. (Pubitemid 39574315)
44. Habib KE, Weld KP, Rice KC, Pushkas J, Champoux M, Listwak S, et al. 2000. Oral administration of a corticotropinreleasing hormone receptor antagonist signifi cantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc Natl Acad Sci USA 97:6079-6084. (Pubitemid 30367526)
45. Hauger RL, Grigoriadis DE, Dallman MF, Plotsky PM, Vale WW, Dautzenberg FM. 2003. International Union of Pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands. Pharmacol Rev 55:21-26. (Pubitemid 36268397)
46. Heinrichs SC, De Souza EB, Schulteis G, Lapsansky JL, Grigoriadis DE. 2002. Brain penetrance, receptor occupancy and antistress in vivo effi cacy of a small molecule corticotropin releasing factor type I receptor selective antagonist. Neuropsychopharmacology 27:194-202. (Pubitemid 34686971)
47. Heinrichs M, Baumgartner T, Kirschbaum C, Ehlert U. 2003. Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress. Biol Psychiatry 54:1389-1398. (Pubitemid 37522163)
48. Hennings JM, Owashi T, Binder EB, Horstmann S, Menke A, Kloiber S, et al. 2009. Clinical characteristics and treatment outcome in a representative sample of depressed inpatients-fi ndings from the Munich Antidepressant Response Signature (MARS) project. J Psychiatr Res 43:215-229.
49. Heuser I, Yassouridis A, Holsboer F. 1994. The combined dexamethasone/CRH test: a refi ned laboratory test for psychiatric disorders. J Psychiatr Res 28:341-356. (Pubitemid 24370022)
50. Holsboer F. 2008. How can we realize the promise of personalized antidepressant medicines? Nat Rev Neurosci 9:638-646.
51. Holsboer F, Ising M. 2008. Central CRH system in depression and anxiety-evidence from clinical studies with CRH1 receptor antagonists. Eur J Pharmacol 583:350-357.
52. Holsboer F, Ising M. 2010. Stress hormone regulation: biological role and translation into therapy. Annu Rev Psychol 61:81-109, C1-11.
53. Holsboer F, von Bardeleben U, Buller R, Heuser I, Steiger A. 1987. Stimulation response to corticotropin-releasing hormone (CRH) in patients with depression, alcoholism and panic disorder. Horm Metab Res Suppl 16:80-88. (Pubitemid 18056661)
54. Horstmann S, Lucae S, Menke A, Hennings JM, Ising M, Roeske D, et al. 2010. Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology 35: 727-740.
55. Illi A, Setala-Soikkeli E, Viikki M, Poutanen O, Huhtala H, Mononen N, et al. 2009. 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression. Neuroreport 20:1125-1128.
56. Ising M, Kunzel HE, Binder EB, Nickel T, Modell S, Holsboer F. 2005. The combined dexamethasone/CRH test as a potential surrogate marker in depression. Prog Neuropsychopharmacol Biol Psychiatry 29:1085-1093. (Pubitemid 41080135)
57. Ising M, Horstmann S, Kloiber S, Lucae S, Binder EB, Kern N, et al. 2007. Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression-a potential biomarker? Biol Psychiatry 62: 47-54. (Pubitemid 46898222)
58. Ising M, Lucae S, Binder EB, Bettecken T, Uhr M, Ripke S, et al. 2009. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry 66:966-975.
59. Juhasz G, Dunham JS, McKie S, Thomas E, Downey D, Chase D, et al. 2011. The CREB1-BDNF-NTRK2 pathway in depression: multiple gene-cognition-environment interactions. Biol Psychiatry 69:762-771.
60. Kanellopoulos D, Gunning FM, Morimoto SS, Hoptman MJ, Murphy CF, Kelly RE, et al. 2011. Hippocampal volumes and the brain-derived neurotrophic factor val66met polymorphism in geriatric major depression. Am J Geriatr Psychiatry 19:13-22.
61. Karg K, Burmeister M, Shedden K, Sen S. 2011. The serotonin transporter promoter variant (5-HTTLPR), stress, and depression meta-analysis revisited: evidence of genetic moderation. Arch Gen Psychiatry 68:444-54.
62. Kaufman J, Yang BZ, Douglas-Palumberi H, Houshyar S, Lipschitz D, Krystal JH, Gelernter J. 2004. Social supports and serotonin transporter gene moderate depression in maltreated children. Proc Natl Acad Sci USA 101: 17316-17321. (Pubitemid 39627817)
63. Kaufman J, Yang BZ, Douglas-Palumberi H, Grasso D, Lipschitz D, Houshyar S, et al. 2006. Brain-derived neurotrophic factor-5-HTTLPR gene interactions and environmental modifi ers of depression in children. Biol Psychiatry 59: 673-680.
64. Kaymak SU, Demir B, Senturk S, Tatar I, Aldur MM, Ulug B. 2010. Hippocampus, glucocorticoids and neurocognitive functions in patients with fi rst-episode major depressive disorders. Eur Arch Psychiatry Clin Neurosci 260:217-223.
65. Keck ME, Welt T, Müller MB, Landgraf R, Holsboer F. 2003a. The high-affi nity non-peptide CRH1 receptor antagonist R121919 attenuates stress-induced alterations in plasma oxytocin, prolactin, and testosterone secretion in rats. Pharmacopsychiatry 36:27-31. (Pubitemid 36384630)
66. Keck ME, Welt T, Muller MB, Uhr M, Ohl F, Wigger A, et al. 2003b. Reduction of hypothalamic vasopressinergic hyperdrive contributes to clinically relevant behavioral and neuroendocrine effects of chronic paroxetine treatment in a psychopathological rat model. Neuropsychopharmacology 28:235-243.
67. Keers R, Uher R, Huezo-Diaz P, Smith R, Jaffee S, Rietschel M, et al. 2011. Interaction between serotonin transporter gene variants and life events predicts response to antidepressants in the GENDEP project. Pharmacogenomics J 11: 138-145.
68. Kimchi-Sarfaty C, Marple AH, Shinar S, Kimchi AM, Scavo D, Roma MI, et al. 2007. Ethnicity-related polymorphisms and haplotypes in the human ABCB1 gene. Pharmacogenomics 8:29-39. (Pubitemid 46157755)
69. Kirchheiner J, Lorch R, Lebedeva E, Seeringer A, Roots I, Sasse J, Brockmoller J. 2008. Genetic variants in FKBP5 affecting response to antidepressant drug treatment. Pharmacogenomics 9:841-846.
70. Kohli MA, Lucae S, Saemann PG, Schmidt MV, Demirkan A, Hek K, et al. 2011. The neuronal transporter gene SLC6A15 confers risk to major depression. Neuron 70:252-265.
71. Künzel HE, Zobel AW, Nickel T, Ackl N, Uhr M, Sonntag A, et al. 2003. Treatment of depression with the CRH-1-receptor antagonist R121919: endocrine changes and side effects. J Psychiatr Res 37:525-533. (Pubitemid 37238946)
72. Kupfer DJ. 2005. Achieving adequate outcomes in geriatric depression: standardized criteria for remission. J Clin Psychopharmacol 25:S24-28. (Pubitemid 41060243)
73. Lancel M, Muller-Preuss P, Wigger A, Landgraf R, Holsboer F. 2002. The CRH1 receptor antagonist R121919 attenuates stress-elicited sleep disturbances in rats, particularly in those with high innate anxiety. J Psychiatr Res 36:197-208. (Pubitemid 34626370)
74. Landgraf R. 2006. Neuropeptides in anxiety and depression. Amino Acids 31:211-213. (Pubitemid 44537048)
75. Lavebratt C, Aberg E, Sjoholm LK, Forsell Y. 2010. Variations in FKBP5 and BDNF genes are suggestively associated with depression in a Swedish population-based cohort. J Affect Disord 125:249-255.
76. Lekman M, Laje G, Charney D, Rush AJ, Wilson AF, Sorant AJ, et al. 2008. The FKBP5-gene in depression and treatment response-an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR D) Cohort. Biol Psychiatry 63:1103-1110.
77. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, et al. 1996. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274:1527-1531. (Pubitemid 26403928)
78. Lewis G, Mulligan J, Wiles N, Cowen P, Craddock N, Ikeda M, et al. 2011. Polymorphism of the 5-HT transporter and response to antidepressants: randomised controlled trial. Br J Psychiatry 198:464-71.
79. Licinio J, O'Kirwan F, Irizarry K, Merriman B, Thakur S, Jepson R, et al. 2004. Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans. Mol Psychiatry 9: 1075-1082. (Pubitemid 40065452)
80. Liebsch G, Landgraf R, Engelmann M, Lorscher P, Holsboer F. 1999. Differential behavioural effects of chronic infusion of CRH 1 and CRH 2 receptor antisense oligonucleotides into the rat brain. J Psychiatr Res 33:153-163. (Pubitemid 29134743)
81. Lin KM, Chiu YF, Tsai IJ, Chen CH, Shen WW, Liu SC, et al. 2011. ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment. Pharmacogenet Genomics 21:163-170.
82. Liu Z, Zhu F, Wang G, Xiao Z, Tang J, Liu W, et al. 2007. Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders. Neurosci Lett 414:155-158. (Pubitemid 46273990)
83. Lucae S, Ising M, Horstmann S, Baune BT, Arolt V, Muller-Myhsok B, et al. 2010. HTR2A gene variation is involved in antidepressant treatment response. Eur Neuropsychopharmacol 20:65-68.
84. Ma XM, Lightman SL. 1998. The arginine vasopressin and corticotrophin-releasing hormone gene transcription responses to varied frequencies of repeated stress in rats. J Physiol 510:605-614. (Pubitemid 28370470)
85. Ma XM, Levy A, Lightman SL. 1997. Emergence of an isolated arginine vasopressin (AVP) response to stress after repeated restraint: a study of both AVP and corticotropin-releasing hormone messenger ribonucleic acid (RNA) and heteronuclear RNA. Endocrinology 138:4351-4357. (Pubitemid 27408481)
86. Malykhin NV, Carter R, Seres P, Coupland NJ. 2010. Structural changes in the hippocampus in major depressive disorder: contributions of disease and treatment. J Psychiatry Neurosci 35:337-343.
87. Mason BL, Pariante CM. 2006. The effects of antidepressants on the hypothalamic-pituitary-adrenal axis. Drug News Perspect 19:603-608. (Pubitemid 46813847)
88. McGowan PO, Sasaki A, D'Alessio AC, Dymov S, Labonte B, Szyf M, et al. 2009. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat Neurosci 12:342-348.
89. McGowan PO, Suderman M, Sasaki A, Huang TC, Hallett M, Meaney MJ, Szyf M. 2011. Broad epigenetic signature of maternal care in the brain of adult rats. PLoS One 6: e14739.
90. Menu P, Gressier F, Verstuyft C, Hardy P, Becquemont L, Corruble E. 2010. Antidepressants and ABCB1 gene C3435T functional polymorphism: a naturalistic study. Neuropsychobiology 62:193-197.
91. Meyer-Lindenberg A. 2008. Impact of prosocial neuropeptides on human brain function. Prog Brain Res 170:463-470. (Pubitemid 352014895)
92. Meyer-Lindenberg A, Domes G, Kirsch P, Heinrichs M. 2011. Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. Nat Rev Neurosci 12: 524-538.
93. Mill J, Petronis A. 2007. Molecular studies of major depressive disorder: the epigenetic perspective. Mol Psychiatry 12: 799-814. (Pubitemid 47347791)
94. Muglia P, Tozzi F, Galwey NW, Francks C, Upmanyu R, Kong XQ, et al. 2010. Genome-wide association study of recurrent major depressive disorder in two European case-control cohorts. Mol Psychiatry 15:589-601.
95. Müller-Myhsok B. 2005. The usefulness of single nucleotide polymorphisms (SNPs) for genetic epidemiological investigation of complex psychiatric diseases. Prog Neuropsychopharmacol Biol Psychiatry 29:1017-1020. (Pubitemid 41080128)
96. Munafo MR, Durrant C, Lewis G, Flint J. 2009a. Gene-environment interactions at the serotonin transporter locus. Biol Psychiatry 65:211-219.
97. Munafo MR, Freimer NB, Ng W, Ophoff R, Veijola J, Miettunen J, et al. 2009b. 5-HTTLPR genotype and anxiety-related personality traits: a meta-analysis and new data. Am J Med Genet B Neuropsychiatr Genet 150B(2):271-281.
98. Neufeld-Cohen A, Tsoory MM, Evans AK, Getselter D, Gil S, Lowry CA, et al. 2010. A triple urocortin knockout mouse model reveals an essential role for urocortins in stress recovery. Proc Natl Acad Sci USA 107:19020-19025.
99. Nierenberg AA, Leon AC, Price LH, Shelton RC, Trivedi MH. 2011. The current crisis of confi dence in antidepressants. J Clin Psychiatry 72:27-33.
100. Nifosi F, Toffanin T, Follador H, Zonta F, Padovan G, Pigato G, et al. 2010. Reduced right posterior hippocampal volume in women with recurrent familial pure depressive disorder. Psychiatry Res 184:23-28.
101. Nikisch G, Eap CB, Baumann P. 2008. Citalopram enantiomers in plasma and cerebrospinal fl uid of ABCB1 genotyped depressive patients and clinical response: a pilot study. Pharmacol Res 58(5-6):344-347.
102. Papiol S, Arias B, Gasto C, Gutierrez B, Catalan R, Fananas L. 2007. Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment. J Affect Disord 104(1-3):83-90. (Pubitemid 350052308)
103. Perlis RH, Fijal B, Dharia S, Heinloth AN, Houston JP. 2010. Failure to replicate genetic associations with antidepressant treatment response in duloxetine-treated patients. Biol Psychiatry 67:1110-1113.
104. Perroud N, Bondolfi G, Uher R, Gex-Fabry M, Aubry JM, Bertschy G, et al. 2011. Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample. Pharmacogenomics 12:365-377.
105. Ressler KJ, Bradley B, Mercer KB, Deveau TC, Smith AK, Gillespie CF, et al. 2010. Polymorphisms in CRHR1 and the serotonin transporter loci: gene x gene x environment interactions on depressive symptoms. Am J Med Genet B Neuropsychiatr Genet 153B(3):812-824.
106. Rudan I. 2010. New technologies provide insights into genetic basis of psychiatric disorders and explain their co-morbidity. Psychiatr Danub 22:190-192.
107. Rupprecht R, Holsboer F. 1999. Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci 22:410-416. (Pubitemid 29453646)
108. Rupprecht R, Rammes G, Eser D, Baghai TC, Schule C, Nothdurfter C, et al. 2009. Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects. Science 325:490-493.
109. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. 2006. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STARD report. Am J Psychiatry 163:1905-1917. (Pubitemid 44807782)
110. Sarginson JE, Lazzeroni LC, Ryan HS, Schatzberg AF, Murphy GM Jr. 2010. FKBP5 polymorphisms and antidepressant response in geriatric depression. Am J Med Genet B Neuropsychiatr Genet 153B(2):554-560.
111. Sato H, Horikawa Y, Iizuka K, Sakurai N, Tanaka T, Shihara N, et al. 2008. Large-scale analysis of glucocorticoid target genes in rat hypothalamus. J Neurochem 106:805-814.
112. Scantamburlo G, Hansenne M, Fuchs S, Pitchot W, Marechal P, Pequeux C, et al. 2007. Plasma oxytocin levels and anxiety in patients with major depression. Psychoneuroendocrinology 32:407-410. (Pubitemid 46617779)
113. Schinka JA, Busch RM, Robichaux-Keene N. 2004. A metaanalysis of the association between the serotonin transporter gene polymorphism (5-HTTLPR) and trait anxiety. Mol Psychiatry 9:197-202. (Pubitemid 38299534)
114. Schroeder M, Krebs MO, Bleich S, Frieling H. 2010. Epigenetics and depression: current challenges and new therapeutic options. Curr Opin Psychiatry 23:588-592.
115. Schüle C. 2007. Neuroendocrinological mechanisms of actions of antidepressant drugs. J Neuroendocrinol 19:213-226. (Pubitemid 46210949)
116. Schüle C, Zill P, Baghai TC, Eser D, Zwanzger P, Wenig N, et al. 2006. Brain-derived neurotrophic factor Val66Met polymorphism and dexamethasone/CRH test results in depressed patients. Psychoneuroendocrinology 31:1019-1025. (Pubitemid 44148919)
117. Schüle C, Baghai TC, Eser D, Rupprecht R. 2009. Hypothalamicpituitary-adrenocortical system dysregulation and new treatment strategies in depression. Expert Rev Neurother 9: 1005-1019.
118. Serradeil-Le Gal C, Wagnon J, Simiand J, Griebel G, Lacour C, Guillon G, et al. 2002. Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl) sulfonyl]-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N, N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist. J Pharmacol Exp Ther 300:1122-1130. (Pubitemid 34165020)
119. Serretti A, Olgiati P, Bajo E, Bigelli M, De Ronchi D. 2011. A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders. World J Biol Psychiatry 12:501-15.
120. Shyn SI, Shi J, Kraft JB, Potash JB, Knowles JA, Weissman MM, et al. 2011. Novel loci for major depression identifi ed by genome-wide association study of sequenced treatment alternatives to relieve depression and meta-analysis of three studies. Mol Psychiatry 16:202-215.
121. Skelton KH, Nemeroff CB, Knight DL, Owens MJ. 2000. Chronic administration of the triazolobenzodiazepine alprazolam produces opposite effects on corticotropin-releasing factor and urocortin neuronal systems. J Neurosci 20:1240-1248. (Pubitemid 30220480)
122. Soravia LM, Heinrichs M, Aerni A, Maroni C, Schelling G, Ehlert U, et al. 2006. Glucocorticoids reduce phobic fear in humans. Proc Natl Acad Sci USA 103:5585-5590.
123. Stein DJ. 2009. Oxytocin and vasopressin: social neuropeptides. CNS Spectr 14:602-606.
124. Strohmaier J, Wust S, Uher R, Henigsberg N, Mors O, Hauser J, et al. 2011. Sexual dysfunction during treatment with serotonergic and noradrenergic antidepressants: Clinical description and the role of the 5-HTTLPR. World J Biol Psychiatry 2: 528-38.
125. Suchanek R, Owczarek A, Kowalczyk M, Kucia K, Kowalski J. 2011. Association between C-281A and val66met functional polymorphisms of BDNF gene and risk of recurrent major depressive disorder in Polish population. J Mol Neurosci 43:524-530.
126. Sullivan PF, de Geus EJ, Willemsen G, James MR, Smit JH, Zandbelt T, et al. 2009. Genome-wide association for major depressive disorder: a possible role for the presynaptic protein piccolo. Mol Psychiatry 14:359-375.
127. Sun RF, Zhu YS, Kuang WJ, Liu Y, Li SB. 2011. The G-712A polymorphism of brain-derived neurotrophic factor is associated with major depression but not schizophrenia. Neurosci Lett 489:34-37.
128. Tanaka M, Telegdy G. 2008. Antidepressant-like effects of the CRF family peptides, urocortin 1, urocortin 2 and urocortin 3 in a modifi ed forced swimming test in mice. Brain Res Bull 75:509-512. (Pubitemid 351381811)
129. Taylor MJ, Sen S, Bhagwagar Z. 2010. Antidepressant response and the serotonin transporter gene-linked polymorphic region. Biol Psychiatry 68:536-543.
130. Terracciano A, Tanaka T, Sutin AR, Sanna S, Deiana B, Lai S, et al. 2011. Genome-wide association scan of trait depression. Biol Psychiatry 68:811-817.
131. Tsai SJ, Hong CJ, Chen TJ, Yu YW. 2007. Lack of supporting evidence for a genetic association of the FKBP5 polymorphism and response to antidepressant treatment. Am J Med Genet B Neuropsychiatr Genet 144B(8):1097-1098. (Pubitemid 350207789)
132. Tsatsanis C, Dermitzaki E, Venihaki M, Chatzaki E, Minas V, Gravanis A, Margioris AN. 2007. The corticotropin-releasing factor (CRF) family of peptides as local modulators of adrenal function. Cell Mol Life Sci 64:1638-1655. (Pubitemid 47036937)
133. Uher R, Caspi A, Houts R, Sugden K, Williams B, Poulton R, Moffi tt TE. 2011. Serotonin transporter gene moderates childhood maltreatment's effects on persistent but not singleepisode depression: Replications and implications for resolving inconsistent results. J Affect Disord [Epub ahead of print].
134. Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M, et al. 2008. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 57:203-209.
135. van Rossum EF, Binder EB, Majer M, Koper JW, Ising M, Modell S, et al. 2006. Polymorphisms of the glucocorticoid receptor gene and major depression. Biol Psychiatry 59: 681-688.
136. van West D, Del-Favero J, Aulchenko Y, Oswald P, Souery D, Forsgren T, et al. 2004. A major SNP haplotype of the arginine vasopressin 1B receptor protects against recurrent major depression. Mol Psychiatry 9:287-292. (Pubitemid 38496720)
137. Vaughan J, Donaldson C, Bittencourt J, Perrin MH, Lewis K, Sutton S, et al. 1995. Urocortin, a mammalian neuropeptide related to fi sh urotensin I and to corticotropin-releasing factor. Nature 378:287-292.
138. Velders FP, Kuningas M, Kumari M, Dekker MJ, Uitterlinden AG, Kirschbaum C, et al. 2011. Genetics of cortisol secretion and depressive symptoms: A candidate gene and genome wide association approach. Psychoneuroendocrinology [Epub ahead of print].
139. von Bardeleben U, Holsboer F. 1988. Human corticotropin releasing hormone: clinical studies in patients with affective disorders, alcoholism, panic disorder and in normal controls. Prog Neuropsychopharmacol Biol Psychiatry 12:S165-187. (Pubitemid 19099188)
140. von Bardeleben U, Holsboer F, Stalla GK, Muller OA. 1985. Combined administration of human corticotropin-releasing factor and lysine vasopressin induces cortisol escape from dexamethasone suppression in healthy subjects. Life Sci 37: 1613-1618. (Pubitemid 15248394)
141. Wankerl M, Wust S, Otte C. 2010. Current developments and controversies: does the serotonin transporter gene-linked polymorphic region (5-HTTLPR) modulate the association between stress and depression? Curr Opin Psychiatry 23: 582-587.
142. Wasserman D, Sokolowski M, Rozanov V, Wasserman J. 2008. The CRHR1 gene: a marker for suicidality in depressed males exposed to low stress. Genes Brain Behav 7:14-19.
143. Weaver IC, Cervoni N, Champagne FA, D'Alessio AC, Sharma S, Seckl JR, et al. 2004. Epigenetic programming by maternal behavior. Nat Neurosci 7:847-854. (Pubitemid 38989508)
144. Weaver IC, Champagne FA, Brown SE, Dymov S, Sharma S, Meaney MJ, Szyf M. 2005. Reversal of maternal programming of stress responses in adult offspring through methyl supplementation: altering epigenetic marking later in life. J
145. Weaver IC, Meaney MJ, Szyf M. 2006. Maternal care effects on the hippocampal transcriptome and anxiety-mediated behaviors in the offspring that are reversible in adulthood. Proc Natl Acad Sci USA 103:3480-3485. (Pubitemid 43346494)
146. Williams LM, Rush AJ, Koslow SH, Wisniewski SR, Cooper NJ, Nemeroff CB, et al. 2011. International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol. Trials 12:4.
147. Willis-Owen SA, Turri MG, Munafo MR, Surtees PG, Wainwright NW, Brixey RD, Flint J. 2005. The serotonin transporter length polymorphism, neuroticism, and depression: a comprehensive assessment of association. Biol Psychiatry 58:451-456. (Pubitemid 41393607)
148. Zak PJ, Stanton AA, Ahmadi S. 2007. Oxytocin increases generosity in humans. PLoS One 2:e1128.
149. Zimmermann U, Spring K, Kunz-Ebrecht SR, Uhr M, Wittchen HU, Holsboer F. 2004. Effect of ethanol on hypothalamicpituitary-adrenal system response to psychosocial stress in sons of alcohol-dependent fathers. Neuropsychopharmacology 29:1156-1165. (Pubitemid 38670052)
150. Zobel AW, Nickel T, Kunzel HE, Ackl N, Sonntag A, Ising M, Holsboer F. 2000. Effects of the high-affi nity corticotropinreleasing hormone receptor 1 antagonist R121919 in major depression: the fi rst 20 patients treated. J Psychiatr Res 34: 171-181. (Pubitemid 30364916)
151. Zou YF, Wang F, Feng XL, Li WF, Tao JH, Pan FM, et al. 2010. Meta-analysis of FKBP5 gene polymorphisms association with treatment response in patients with mood disorders. Neurosci Lett 484:56-61.